Table 5 Perceived benefits and challenges regarding the current individualized (X) DR TB treatment
| Â | Â | Indonesia | Kyrgyzstan | Nigeria |
|---|---|---|---|---|
Acceptability | Perceived benefits regarding the current ITR | • Proven efficacy according to WHO • Monitoring and management of AEs covered by health insurance • Enablers and nutrition provided with the regimen | • Reduced side effects of current ITR compared to the one before • Good completion rates • No resistance yet | • Use in children possible • Funding for drugs through the Global Fund • Monitoring also funded |
Perceived challenges regarding the current ITR | • Long duration of treatment • High pill burden • High health worker and health facility workload • Side effects common • Injectables | |||
• Difficulty in quantification and forecasting due to individual dosing | • Limited adherence • Difficulties with treatment monitoring • Difficulties in allocating treatment in children | • Injectables (resulting in AEs and high HR needs) • Hospitalization • High workload on home visits if home-based care setting • Diagnostic treatment gap due to lack of funding for travel for baseline investigations • Limited adherence • Lack of tests for all examinations for AEs • High cost for monitoring • Difficulty in quantification and forecasting due to individual dosing | ||